Clinica chimica acta; international journal of clinical chemistry · 2025
Decoding liver injury: Vitamin D3 metabolite fingerprints in cholestatic liver disease diagnosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qiu Lanlan, Zhang Lin, Hua Lei, Wu Qiong, Cao Xinghao, Du Yiping, Wei Bo, Wu Ting
Аннотация
BACKGROUND: Conventional indicators for diagnosing liver injury in cholestatic liver diseases (CLD) include a combination of biochemical, imaging, and clinical assessments, which are critically limited by non-specificity, delayed detection windows, and poor correlation with cholestasis-specific mechanisms, underscoring the need for novel biomarker-driven strategies. Emerging biomarkers (e.g., vitamin D metabolites) are being explored to improve early diagnosis and specificity in liver injury assessment.
METHODS: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed for simultaneous quantification of 25-hydroxyvitamin D3 [25-(OH)-D3], 1,25-dihydroxyvitamin D3 [1,25-(OH)2-D3], 24,25-dihydroxyvitamin D3 [24,25-(OH)2-D3], and the vitamin D metabolite ratio (VMR), providing a robust framework for assessing both systemic vitamin D deficiency and cholestatic liver injury severity. To interrogate vitamin D3 metabolism dynamics in CLD progression, statistical analyses-one-way ANOVA, correlation analysis, receiver operating characteristic (ROC) curves, and heatmaps-were applied to evaluate associations between metabolic profiles and liver injury severity.
RESULTS: Stratified by the Child-Pugh scoring system, serum levels of 25-(OH)-D3, 1,25-(OH)2-D3, 24,25-(OH)2-D3, and VMR exhibited a progressive decline across cohorts-healthy controls (HC), moderate liver injury (MLI), and severe liver injury (SLI)-correlating inversely with advancing disease severity. Notably, 24,25-(OH)2-D3 demonstrated superior diagnostic accuracy for CLD, achieving an area under the curve (AUC) of 0.994. Robust correlations between 25-(OH)-D3 and 24,25-(OH)2-D3 were observed in all cohorts (HC, MLI, SLI), though the regression slopes progressively attenuated in MLI and SLI cohorts, indicating preserved but diminished metabolic flux from 25-(OH)-D3 to 24,25-(OH)2-D3 as liver injury worsened. This attenuation aligns with progressive functional impairment in vitamin D3 metabolism. Clinically, post-treatment profiling following one week of hospitalization revealed that 25-(OH)-D3 exhibited superior sensitivity in tracking therapeutic responses compared to conventional cholestatic liver disease (CLD) indicators, underscoring their utility as dynamic biomarkers.
CONCLUSIONS: The metabolites, particularly 24,25-(OH)2-D3, demonstrated excellent diagnostic accuracy for liver injury in CLD, while 25-(OH)-D3 outperformed conventional indicators in monitoring therapeutic response during cholestasis management.
METHODS: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed for simultaneous quantification of 25-hydroxyvitamin D3 [25-(OH)-D3], 1,25-dihydroxyvitamin D3 [1,25-(OH)2-D3], 24,25-dihydroxyvitamin D3 [24,25-(OH)2-D3], and the vitamin D metabolite ratio (VMR), providing a robust framework for assessing both systemic vitamin D deficiency and cholestatic liver injury severity. To interrogate vitamin D3 metabolism dynamics in CLD progression, statistical analyses-one-way ANOVA, correlation analysis, receiver operating characteristic (ROC) curves, and heatmaps-were applied to evaluate associations between metabolic profiles and liver injury severity.
RESULTS: Stratified by the Child-Pugh scoring system, serum levels of 25-(OH)-D3, 1,25-(OH)2-D3, 24,25-(OH)2-D3, and VMR exhibited a progressive decline across cohorts-healthy controls (HC), moderate liver injury (MLI), and severe liver injury (SLI)-correlating inversely with advancing disease severity. Notably, 24,25-(OH)2-D3 demonstrated superior diagnostic accuracy for CLD, achieving an area under the curve (AUC) of 0.994. Robust correlations between 25-(OH)-D3 and 24,25-(OH)2-D3 were observed in all cohorts (HC, MLI, SLI), though the regression slopes progressively attenuated in MLI and SLI cohorts, indicating preserved but diminished metabolic flux from 25-(OH)-D3 to 24,25-(OH)2-D3 as liver injury worsened. This attenuation aligns with progressive functional impairment in vitamin D3 metabolism. Clinically, post-treatment profiling following one week of hospitalization revealed that 25-(OH)-D3 exhibited superior sensitivity in tracking therapeutic responses compared to conventional cholestatic liver disease (CLD) indicators, underscoring their utility as dynamic biomarkers.
CONCLUSIONS: The metabolites, particularly 24,25-(OH)2-D3, demonstrated excellent diagnostic accuracy for liver injury in CLD, while 25-(OH)-D3 outperformed conventional indicators in monitoring therapeutic response during cholestasis management.